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Background
Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with
poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past
decade, reduced intensity conditioning regimens have been shown to offer results similar to
those of conventional high-dose conditioning regimens but with lower toxicity early after
transplantation, especially in patients with chemosensitive disease at transplant. 
Design and Methods
The aim of this study was to analyze the long-term outcome of patients with follicular lym-
phoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced
intensity conditioning regimen within prospective trials. The prospective multicenter studies
considered included 37 patients with follicular lymphoma who underwent allogeneic stem cell
transplantation between 1998 and 2007 with a fludarabine plus melphalan-based reduced
intensity conditioning regimen.
Results
The median age of the patients was 50 years (range, 34-62 years) and the median follow-up
was 52 months (range, 0.6 to 113 months). Most patients (77%) had stage III-IV at diagnosis,
and patients had received a median of three lines of therapy before the reduced intensity con-
ditioning allogeneic stem cell transplantation. At the time of transplantation, 14 patients were
in complete remission, 16 in partial remission and 7 had refractory or progressive disease after
salvage chemotherapy. The 4-year overall survival rates for patients in complete remission, par-
tial remission, or with refractory or progressive disease were 71%, 48% and 29%, respective-
ly (P=0.09), whereas the 4-year cumulative incidences of non-relapse mortality were 26%
(95% CI, 11-61), 33% (95% CI, 16-68) and 71% (95% CI, 44-100), respectively. The incidence
of relapse for the whole group was only 8% (95% CI, 2-23).  
Conclusions
We conclude that this strategy of reduced intensity conditioning allogeneic stem cell transplan-
tation may be associated with significant non-relapse mortality in heavily pre-treated patients
with follicular lymphoma, but a remarkably low relapse rate. Long-term survival is likely in
patients without progressive or refractory disease at the time of transplantation.
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Introduction 
Among patients with follicular lymphoma (FL), allo-
geneic hematopoietic stem cell transplantation (SCT) was
initially used in those patients who relapsed after autolo-
gous SCT or who were not candidates for autologous SCT
because of the extent of their disease or marrow involve-
ment. The results of several retrospective, comparative
studies between allogenic and autologous SCT suggested
that allogenic SCT was associated with a very low relapse
rate and might be a curative option for FL.1-4 The presumed
advantage of allogeneic SCT was attributed in part to a
graft-versus-lymphoma (GVL) effect. This presumption
was supported by several studies, which showed very low
rates of relapse.1-7 However, the benefit of allogeneic SCT
was counteracted by a high non-relapse mortality (NRM)
rate.1,4 With the aim of reducing NRM while retaining the
GVL effect, reduced intensity conditioning (RIC) regimens
were developed for allogeneic SCT.8,9
RIC extends the indication for allogeneic SCT to older
and less medically fit patients. This strategy has shown
comparable results to high-dose conditioning regimens for
several hematologic diseases.10-12 A recent report from the
CIBMTR registry also supports the use of RIC allogeneic
SCT in patients with FL.9 However, the risk of organ tox-
icity and infections associated with graft-versus-host dis-
ease (GVHD) is still a major concern in this setting.
Robinson et al. reported a disappointing 39% NRM and
29% progression-free survival at just 1 year for patients
with FL after RIC allogeneic SCT.12 In line with such
results, restrospective studies by Vigouroux et al. and
Rezvani et al. also reported high NRM rates in patients
with low-grade lymphoma following various RIC allo-
geneic SCT strategies.6,13
The anti-tumor effect of RIC allogeneic SCT is based at
least partly on the GVL effect, which is usually associated
with GVHD, especially chronic GVHD; the presence of a
GVL effect in FL is suggested by the encouraging results
reported by Khouri et al. for patients with chemosensitive
FL conditioned with a fludarabine, cyclophosphamide and
rituximab-based non-myeloablative protocol, without T-
cell depletion in most cases: the estimated overall survival
and progression-free survival rates of these patients were
85% and 83%, respectively, at a median follow-up of 60
months.14 The French group also reported a very low
relapse rate (9%) after a long follow-up in patients with
low-grade lymphoma who received various RIC allogene-
ic SCT protocols.6 In contrast, in a study by Morris et al.,15
the incidence of relapse among patients who received a
RIC allogeneic SCT protocol which incorporated in vivo T-
cell depletion with alemtuzumab, in combination with
fludarabine and melphalan, was relatively high (44%).
The published studies on RIC allogeneic SCT in FL are
mostly retrospective and often include several different
conditioning regimens or have a short follow-up. The pur-
pose of the current study was to determine the long-term
outcome of patients with advanced FL who were entered
in consecutive prospective RIC allogeneic SCT trials car-
ried out in Spain; in contrast to many previous studies, a
homogeneous conditioning regimen was used in these tri-
als, and the GVHD prophylaxis, donor type and stem cell
source were also homogeneous.
Design and Methods
Patients
The current study includes 37 patients diagnosed with FL
grade I to III who were included in two prospective protocols,
which were run in parallel in nine Spanish stem cell transplanta-
tion centers from October 1999 to August 2007. Twenty-five
(68%) of the 37 patients were included in the prospective trial
registered as MINIALO-99-00/270, in which the dose of melpha-
lan used was 140 mg/m2, while the remaining 12 (32%) patients
were included in the GELTAMO-99-0151 study in which the
dose of melphalan was 80 mg/m2. Patients with relapsed or
refractory FL who were not candidates for autologous transplan-
tation and who had a suitable HLA identical related donor were
eligible for inclusion in the study. Patients were required to have
an ECOG performance status score of 2 or lower, serum biliru-
bin lower than 2 mg/dL, serum creatinine lower than 1.6 mg/dL,
no symptomatic cardiac or pulmonary disease, and no active
infection. All participants gave written informed consent to par-
ticipation in the studies, which were approved by the national
and local ethics committees. All data records were obtained
from the Grupo Español de Linfomas/ Transplante de Médula Osea
(GELTAMO) database, and were completed by each center. All
donors were HLA-identical siblings and the source of stem cells
was granulocyte colony-stimulating factor-mobilized peripheral
blood stem cells in all cases. 
Conditioning and graft-versus-host disease prophylaxis
The conditioning regimen used has been described in detail
elsewhere.16 Briefly, fludarabine (125-150 mg/m2) was combined
with melphalan (80-140 mg/m2). GVHD prophylaxis consisted
of cyclosporine A from day -7 plus methotrexate (10 mg/m2),
administered on days +1, +3, and +6 and, in five cases, also on
day +11. All patients received standard antimicrobial prophylax-
is during the early post-transplant period.
Hematopoietic recovery, graft-versus-host disease
assessment and chimerism analyses
Neutrophil and platelet engraftment were defined as the first
of three consecutive days with an absolute neutrophil count of
greater than 0.5¥109/L and an untransfused platelet count of
greater than 20¥109/L, respectively.
The diagnosis of acute GVHD was based on the classical clin-
ical presentation with confirmatory pathological findings in all
patients. Acute and chronic GVHD were assessed and graded
according to published criteria.17,18
Chimerism was evaluated between days 21 and 28 after trans-
plantation and every 15 days thereafter until complete T-cell
donor chimerism was achieved. The chimerism analyses were
done in separated T cells and granulocytes from peripheral
blood in most patients (n=28). Chimerism was determined using
polymerase chain reaction analysis of informative minisatellite
loci, as previously described.19 Complete donor chimerism was
defined as the presence of at least 95% donor DNA in the sam-
ple analyzed.
Clinical evaluation and response assessment 
Patients underwent computed tomography of the chest,
abdomen and pelvis, and bone marrow aspiration and biopsies
with immunohistochemical and flow cytometric immunophe-
notyping analysis. Disease stage was evaluated using the Ann
Arbor criteria. Patients were evaluated for disease stage and
response at 3, 6, and 12 months after transplantation and every
6 months thereafter. Responses were evaluated according to
standard criteria for patients with lymphoma, as described by
RIC allogeneic SCT in follicular lymphoma
haematologica | 2010; 95(7) 1177
Cheson et al.20 A complete response was defined as the complete
disappearance of all detectable clinical, pathological (i.e. bone
marrow) and radiographic evidence of disease, and all disease-
related symptoms as well as the normalization of all biochemi-
cal abnormalities. A partial response was defined as a decrease
of at least 50% of all measurable lesions. Stable disease was
defined as no response or a less than 50% decrease in measura-
ble lesions. Progressive disease was defined as at least a 50%
increase of any measurable lesion or appearance of any new
lesion during or after therapy.
Statistical analysis
The primary end-point of this study was to analyze the long-
term overall survival after RIC allogeneic SCT. Secondary end-
points were to analyze the regimen-related toxicity, disease-free
survival, relapse rate, and NRM, as well as to verify the impact of
possible prognostic factors for these outcomes. The incidences of
acute and chronic GVHD, NRM and relapse were calculated using
cumulative incidence estimates, taking into account competing
risks.21 The probability of overall survival was estimated from the
time of transplantation using Kaplan-Meier curves22 and com-
pared using the Tarone-ware and log rank tests. Median times
were compared by Wilcoxon’s rank sum test. Risk factors for
NRM were estimated using a univariate Cox regression model;
multivariate analyses were not done because of the small number
of patients. All tests of significance were two-sided, with P levels
of 0.05 or less being considered statistically significant. All statis-
tical analyses were performed using SPSS version 15.0 (SPSS,
Chicago, IL, USA), with the exception of the cumulative incidence
analyses, which were carried out with NCSS 2004 (Number
Cruncher Statistical System, Kaysville, UT, USA).
Results
Patients’ characteristics
The patients’ characteristics are summarized in Table 1.
We first compared the patients’ characteristics, toxicity
profile and outcomes according to the melphalan dose, and
found no differences in conditioning-related toxicity,
engraftment kinetics, occurrence and timing of GVHD, or
any post-transplant outcomes (data not shown). There were
26 (71%) male patients with a median age of 50 years
(range, 34 to 62 years). The time from diagnosis to trans-
plantation ranged from 1 to 12 years (median of 4 years).
Most patients had been heavily pretreated (59% of patients
had received three or more lines of chemotherapy) prior to
the RIC allogeneic SCT. Thirty patients (82%) were trans-
planted with sensitive disease and 18% with refractory dis-
ease. Fourteen patients transplanted in complete remission
had been heavily pretreated with a median of three lines
(range, 2 to 5 lines) of systemic therapy, and 46% of the
patients had previously undergone autologous SCT.
Toxicity
As shown in Table 2, the main conditioning-related tox-
icity was gastro-intestinal. Seventeen (46%) patients suf-
fered nausea or vomiting, but only six had grade 2 emesis
and one had grade 3. Mucositis grades II-IV was observed
in 16 (43%) of the 37 patients, and diarrhea in 10 (27%)
cases, which was grade 3 in only one case. Overall, only
six (16%) patients had grade III to IV toxicity. Only one
patient died from toxicity directly attributed to the condi-
tioning regimen (death on day +18 from a severe sinu-
soidal obstruction syndrome).
Hematopoietic recovery and chimerism analyses
The median times of neutrophil and platelet recovery as
well as other post-transplant outcomes are shown in Table
2. Information on peripheral blood leukocyte subset
chimerism was available for 28 patients. Twenty-seven
(96%) of the 28 patients studied achieved complete donor
T-cell chimerism at a median time of 32 days (range, 23-90
days) after transplantation.
J.L. Piñana et al.
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Table 1. Patients’ characteristics before RIC allogeneic stem cell trans-
plantation.
Characteristics (n= 37)
Recipients median age, years (range) 50 (34-62)
Male sex, n (%) 26 (71)
Female sex donor, n (%) 22 (60)
Female donor to male recipient, n (%) 14 (38)
Underlying disease, n (%)
Stage III-IV Ann Arbor at diagnosis 28 (77)
Histology grade III, n (%) 4 (11)
ECOG performance status at allogeneic SCT, n (%)
0 18 (49)
> 0 19 (51)
Number of prior therapies, n (%)
2 15 (41)
3 13 (32)
>3 10 (27)
Prior fludarabine, n (%) 18 (49)
Prior anti-CD 20, n (%) 13 (35)
Prior autologous SCT, n (%) 17 (46)
Disease status at RIC allogeneic SCT, n (%)
Complete remission 14 (39)
Partial remission 16 (43)
No response or progressive disease 7 (18)
Donor CMV status, n (%) 29 (80)
Patient CMV seropositive 31 (85)
Median time Dx to allogeneic SCT, years (range) 4 (1-12)
Graft content CD34+cells ¥106/kg, median (range) 5.1 (3-15.6)
CMV:, cytomegalovirus; Dx: diagnosis.
Figure 1. Overall survival according to the status of the FL at the
time of transplantation. PROG; patients with no response or progres-
sive disease prior to RIC allogeneic SCT; PR: patients in partial
remission prior to the transplant; CR: patients in complete remission
prior to the transplant.
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Graft-versus-host disease
The details on the characteristics and incidence of acute
and chronic GVHD are shown in Table 2. Acute GVHD
grades I-IV was diagnosed in 19 (53%) of 36 evaluable
patients with a median onset at 32 days (range, 19-97
days). Five patients had grade IV acute GVHD, three had
grade III, nine had grade II and two developed grade I
acute GVHD. Steroid-refractory acute GVHD occurred in
six (31%) of the 19 patients. Nine patients were not
assessable for chronic GVHD, since they died before day
+120. Twenty-two of 28 (78%) evaluable patients devel-
oped chronic GVHD, and 12 (42%) of them had extensive
chronic GVHD. 
Non-relapse mortality
With a median follow-up for all 37 patients of 52
months, 15 (41%) patients had died, 13 due to transplant-
related complications at a median time after allogeneic
SCT of 94 days (range, 18-1567 days) and two due to dis-
ease progression. The most common causes of NRM were
GVHD and infections (four patients died from GVHD
with infection, three from GVHD without infection, four
from infection without active GVHD and two from other
causes). Univariate analysis for NRM identified refractory
or progressive FL before transplant as the only risk factor
for NRM (univariate HR 3; 95% CI 1.01-8.8; P=0.04).
Other variables such as age, sex, time from diagnosis to
transplant, stage at diagnosis, prior anti-CD20 therapy,
prior fludarabine, prior autologous SCT, number of treat-
ment lines before transplantation, ECOG performance sta-
tus and donor sex mismatch did not show any impact on
NRM.
Disease response
Table 3 summarizes the response to transplant and
other outcomes. Twenty-eight patients were evaluable for
disease status at 3-4 months after RIC allogeneic SCT,
while nine patients were not evaluable because of early
death (NRM before day +120). Fifteen of 23 patients
(63%) with active disease (partial response, refractory dis-
ease or progression of FL) at the time of transplantation
showed a response to the transplant (14 achieved a com-
plete remission and one a partial remission). As shown in
Table 3, three of seven patients transplanted with refracto-
ry or progressive disease were evaluable and all three
responded (two complete remissions and one partial
remission) after developing acute followed by chronic
GVHD. At last follow-up both patients who had a com-
plete response remain in remission with extensive chron-
RIC allogeneic SCT in follicular lymphoma
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Table 2. Toxicity, hematopoietic recovery and transplant outcome.
Transplant outcome Results
Median days to hematologic recovery, days (range)
Neutrophil count > 0.5¥109/L 15 (10-19)
Platelet count > 20¥109/L 11 (5-25)
Transplant-related toxicities during neutropenia
Mucositis grade II-IV, n (%) 16 (43)
Nausea-vomiting, n (%) 17 (46)
Acute renal failure, n (%) 7 (18)
Diarrhea, n (%) 10 (27)
Liver, n (%) 9 (25)
Neurological/cardiological, n (%) 3 (8) /3 (8)
Median time to T-cell CDC, days (range) * 32 (22-90)
Acute GVHD
Cum. Inc. of acute GVHD II-IV,  % (95% C.I.) 51 (32-65)
Median onset, days (range) 32 (19-97)
Chronic GVHD n/evaluable patients 22/28
Cum. Inc. of chronic GVHD at 4-years, %  (95% C.I.) 88 (77-100)
Median onset in days (range) 137 (102-400)
Cum. Inc. of extensive chronic GVHD, %  (95% C.I.) 53 (38-76)
NRM, % (C.I. 95%)
At day +100 24 (13-42)
At 4 years 37 (25-57)
Cum Inc of relapse at 4 years,  %  (95% C.I.) 8 (2-23)
Disease-free survival at 4 years,  %  (95% C.I.) 55% (46-63)
Overall survival at 4 years,  %  (95% C.I.) 57% (48-65)
Median follow-up, months  (range) 52 (0.6-113)
Cum. Inc.: cumulative incidence; CI: confidence interval; CDC: complete donor
chimerism; GVHD: graft-versus-host disease; NRM: non-relapse mortality; *Available in
28 patients, 27 of whom obtained T-cell CDC, while one patient  died of acute GVHD
grade IV on day +73 after transplant, before CDC was identified.
Table 3. Response to transplant and other outcomes according to disease status at transplantation and the development of graft-versus-host
disease.
Disease status N. with acute GVHD Status at OS at day N. with chronic GVHD Outcome after OS at Final outcome or disease
/n. evaluable day +120 +120 / n. evaluable* day +120 4 years status at last follow-up
2 CR 2 CR 2 CR
PROG (n= 7) 6/7 1 PR§ 43% 3/3 29%
4 NRM 1 NRM 5 NRM
PR (n= 16) 6/15 Þ 12 CR 10 CR 10 CR
2 NR† 88% 11/14 2 PROGa 48% 2 deaths from lymphoma
2 NRM 2 NRM 4 NRM
10 CR 10 CR 10 CR
CR (n= 14) 6/14 1 PROGb 78% 8/11 71%
3 NRM 1 NRM 4 NRM
PROG: non-responders or progression before reduce intensity conditioning allogeneic stem cell transplantation (Allo-RIC); PR= partial remission before Allo-RIC; CR= complete
remission before Allo-RIC; GVHD: graft-versus-host disease; n: number; OS: overall survival;* Refers to patients alive on day +120. Þ One patient in PR died before engraftment and
was not evaluable for acute GVHD. §This patient in PR on day +120 achieved CR after the onset of chronic GVHD; in the same group, four patients died before day +100 and were
thus not evaluated for disease status. †Two patients classified as non response (NR) had stable disease (same PR as pre-Allo-RIC); one of these patients died from disease progres-
sion and the other achieved prolonged CR after the onset of chronic GVHD. aOne of  these patients was in CR at day +120 but died later due to progressive disease without hav-
ing developed chronic GVHD, even after donor lymphocyte infusions. bThis patient did not develop acute GVHD and progressed on day +117 but achieved a new prolonged CR
after the onset of chronic GVHD.
ic GVHD, while the patient with a partial remission died
due to a non-relapse-related cause. 
Among the patients transplanted in partial remission, 14
were evaluable for response, and 12 achieved a complete
remission by 3 months post-transplant while two had sta-
ble disease. One patient with stable disease reached a
complete remission at day +206, upon developing chronic
GVHD. The other patient with stable disease showed pro-
gressive disease 166 days after transplantation, without
having developed chronic GVHD, and died. One patient
who was in complete remission on day +120 relapsed on
day +122; the patient did not develop GVHD despite
donor lymphocyte infusions and died from FL.
Finally, among the 14 patients who were in complete
remission at the time of allogeneic SCT, ten (71%) remain
in complete remission, three died early after the transplant
and one patient relapsed on day +117, but after rapid
tapering of the cyclosporine A dose, he developed chron-
ic GVHD and a new complete remission was obtained,
which is ongoing 102 months after the allogeneic trans-
plant. 
Relapse, overall survival and disease-free survival
Relapse or progression occurred in only three patients at
a median time post-transplant of 122 days (range, 117-166
days), and two of these patients died from disease pro-
gression, while one obtained a prolonged complete remis-
sion, as described above. The median overall survival for
the whole group was 85 months (range, 16-112 months) at
last follow-up, and the probability of overall survival at 4
years was 54%. According to the disease status at trans-
plantation, the overall survival was 29%, 48% and 71%
for patients with refractory or progressive disease, partial
remission and complete remission at transplantation,
respectively (P=0.09) (Figure 1). The 4-year probability of
disease-free survival for the whole group was 57%, with
a median follow-up in surviving patients of 87 months
(range, 16-113 months). The disease-free survival for
patients with refractory or progressive disease, partial
remission and complete remission at transplantation was
29%, 48% and 64%, respectively (P=0.2).
Discussion
This prospective multicenter study has a long follow-up
and reports on the efficacy of a homogeneous RIC regi-
men in patients with advanced FL undergoing allogeneic
SCT, showing 4-year overall and disease-free survival
rates above 50%. The results of larger, previously report-
ed series, which were mostly analyzed retrospectively, are
summarized in Table 4. Although direct comparisons of
the results of the studies are quite difficult to interpret
given the important differences in study populations and
follow-up periods, in line with previous reports, the
relapse rate in our study was very low (8%), and a GVL
effect was apparent, with some durable responses seen
only after the onset of chronic GVHD. This finding is,
however, in contrast with the higher relapse rate (44%)
reported by Morris et al. in a study in which a similar reg-
imen was used but with the addition of alemtuzumab in
order to decrease GVHD,14 thus highlighting the impor-
tance of a GVL effect in this indolent malignancy, which is
usually linked to the appearance of acute and/or chronic
GVHD. Nevertheless, and as reported by Vigouroux et al.,6
the day +100 and 4-year NRM were high. Progressive or
refractory disease at the time of transplantation was asso-
ciated with a significantly higher NRM, emphasizing that
selection of patients is crucial for current RIC allogeneic
SCT strategies to be successful. Recent studies by Khouri
et al.14 and Corradini et al.23 showed similar relapse rates
with better overall survival due to lower NRM. The differ-
ences between the results are probably due to the fact that
our cohort of patients, unlike those of the other studies,
included patients with progressive/chemorefractory dis-
ease. In fact, irrespective of the type of non-Hodgkin’s
lymphoma, patients with refractory disease fare very
poorly.4,24,25 Other relevant differences between the studies
were the high number of patients in our cohort in whom
J.L. Piñana et al.
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Table 4. Reports of major series of patients with non-Hodgkin’s lymphoma undergoing RIC allogeneic stem cell transplantation.
Authors Patients Conditioning Refractory* Median Relapse or Progression-free Overall Non
(n) % follow-up progression survival (%) survival (%) relapse
months (%) mortality (%)
(range)
Rezvani, 62‡ (54 FL) Fluda + 23 36.6 (na) 38 (Transf.) 21 (Transf) 18 (Transf) 42
et al.13 TBI 200 cGy 14 (Indolent.) 54 (Indolent) 67 (Indolent)
Khouri, et al.14 47 FL Fluda + Cy ± R 0 60 (19-94) 4 85 83 14
Faulkner 28† BEAM + na 17 (1-67) 20 69 74 16
et al.5 alemtuzumab
Corradini, 53† Fluda + Cy + na 31 (6-70) na 73 66 18
et al.21 Thiotepa
Vigoroux 73† Fluda + ATG + 26 37 (16-77) 9.6 51 56 40
et al.6 Bu
Fluda + TBI
Morris, 41† (FL 29) Fluda + Mel + 24 36 (18-60) 44 55 73 11
et al.15 alemtuzumab
*Percentage of patients refractory at transplant. †Follicular and other indolent lymphomas are included. ‡Also transformed lymphomas. FL: follicular lymphoma; TBI: total body irra-
diation; na: not available. Fluda: fludarabine; Cy: cyclophosphamide; R: rituximab; ATG: antithymocyte globulin; Bu: bulsulfan; Mel: melphalan.
a prior autologous SCT had failed (46%), and the large
proportion of patients who did not have an ideal perform-
ance status (19/37 had ECOG performance status >0), a
variable that has been associated with an increased risk of
NRM.24 With minimal-intensity non-myeloablative condi-
tioning, Rezvani et al.13 reported that patients with refrac-
tory disease at transplantation were five times more like-
ly to relapse and two times more likely to experience
NRM compared to patients with chemosensitive disease.
Thus, to reduce the NRM associated with current RIC
allogeneic SCT protocols it seems reasonable to try to
select patients earlier in their disease course and use novel
salvage strategies, such as new monoclonal antibodies or
radio-immunotherapy, in order to obtain at least a partial
remission before transplantation, as suggested by most
authors.4,25,26
As expected, the fludarabine-melphalan conditioning
regimen was shown to have a direct anti-tumor response
in many patients, since disease evaluation early after trans-
plantation showed that 15/23 (63%) of patients with meas-
urable disease obtained a response, which was a complete
remission in most cases (Table 3). However, a GVL effect
was also noted, since three patients with measurable dis-
ease both before and after allogeneic transplantation did
not develop acute GVHD but showed a durable complete
remission after developing chronic GVHD, and one patient
who was in complete remission before transplantation had
early disease progression without acute GVHD but
achieved a complete remission after the onset of de novo
chronic GVHD. In addition, the two patients who died
from disease progression after day +120 had not developed
GVHD, while none of the 22 patients who did develop
chronic GVHD had progression of their FL, with 22
patients alive in complete remission after a long follow-up.
The high incidence of acute (51%) and chronic (88%)
GVHD is characteristic of most RIC allogeneic SCT proto-
cols that do not include in vivo T-cell depletion with
antithymocyte globulin or, especially, alemtuzumab.
Although the rate of disease progression may be higher
with in vivo T-cell depletion, donor lymphocyte infusions
may lead to a high proportion of new complete remissions,
and thus the current disease-free survival rate following T-
cell depleted RIC allogeneic protocols may be significantly
higher than the standard disease-free survival rate.5,14
Donor lymphocyte infusions may also be given to patients
with low or decreasing mixed chimerism with the inten-
tion of achieving full donor chimerism, even when there is
no disease progression. Of course, such infusions carry the
risk of inducing GVHD, which may be severe. On the
other hand T-cell-replete transplants are expected to lead to
higher incidences of acute and chronic GVHD, which may
lead to a higher NRM that may counterbalance the positive
GVL effect, thus lowering the disease-free survival rate.
The need for donor lymphocyte infusions in this setting is,
of course, much less. Perhaps a preference for any of these
strategies should depend partly on the risk of disease recur-
rence at the time of transplantation.
In summary, this prospective study reports the long-
term follow-up of a cohort of patients with advanced and
heavily pretreated FL who underwent RIC and an allo-
geneic SCT with a homogeneous transplant strategy, con-
firming that long-term disease-free survival was obtained
in more than half of these patients, especially in those
whose FL was not in frank progression at the time of
transplantation; both the direct anti-tumor effect of the
fludarabine-melphalan combination and a GVL effect are
responsible for these prolonged remissions. 
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